Power Law company profile

Aerie Pharmaceuticals

Biotech & Life Sciences · Durham, United States · Founded 2005 · IPO 2013 Thoroughbred

Innovative ophthalmic therapies for glaucoma, dry eye, and retinal diseases

Valuation

$918M

Market cap · 2026

Revenue

$213M

Latest reported FY

Featured in $10B+ revenueThoroughbred · Power Law outcome

Investors

7 investors on Aerie Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage

TPG Biotech

TPG

Alta Partners

Series B+ 4 investors entered at this stage

Duke University

Sofinnova Investments

Osage University Partners

Clarus Ventures

Global footprint

Where Aerie Pharmaceuticals has talent and traffic

Workforce by country

1 countries with
team presence

🇮🇪 Ireland100%

1 country shown

Market sentiment

What the market is saying about Aerie Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Aerie Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aerie Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles